The results showed that patients with overexpression of OTUB2 indicated a shorter overall survival, first progression [the time from progression-free survival to the beginning of tumor progression after treatment (24)] and post progression survival (the time from tumor progression to death after treatment) compared with the patients with low expression of OTUB2 (Figure 1E). This evidence concerns the gene OTUB2 and neoplasm.